Pseudouridine as a novel biomarker in prostate cancer. Academic Article uri icon


  • Epitranscriptomic analysis has recently led to the profiling of modified nucleosides in cancer cell biological matrices, helping to elucidate their functional roles in cancer and reigniting interest in exploring their use as potential markers of cancer development and progression. Pseudouridine, one of the most well-known and the most abundant of the RNA nucleotide modifications, is the C5-glycoside isomer of uridine and its distinctive physiochemical properties allows it to perform many essential functions. Pseudouridine functionally (a) confers rigidity to local RNA structure by enhancing RNA stacking, engaging in a cooperative effect on neighboring nucleosides that overall contributes to RNA stabilization (b) refines the structure of tRNAs, which influences their decoding activity (c) facilitates the accuracy of decoding and proofreading during translation and efficiency of peptide bond formation, thus collectively improving the fidelity of protein biosynthesis and (e) dynamically regulates mRNA coding and translation. Biochemical synthesis of pseudouridine is carried out by pseudouridine synthases. In this review we discuss the evidence supporting an association between elevated pseudouridine levels with the incidence and progression of human prostate cancer and the translational significance of the value of this modified nucleotide as a novel biomarker in prostate cancer progression to advanced disease.

published proceedings

  • Urol Oncol

altmetric score

  • 20.6

author list (cited authors)

  • Stockert, J. A., Weil, R., Yadav, K. K., Kyprianou, N., & Tewari, A. K.

citation count

  • 8

complete list of authors

  • Stockert, Jennifer A||Weil, Rachel||Yadav, Kamlesh K||Kyprianou, Natasha||Tewari, Ashutosh K

publication date

  • January 2021